

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Request	Application Number	09/772,938	
For (DOF)	Filing Dat	January 31, 2001	
Continued Examination (RCE) Transmittal	First Named Inventor	NABIL HANNA	
Address to:	Art Unit	1644	
Mail Stop RCE Commissioner for Patents	Examiner Name	Phillip Gambel	
P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket Number	037003-0276658	
This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.			
 Submission required under 37 CFR 1.114 No amendments enclosed with the RCE will be entered in the applicant does not wish to have any previously filed uner amendment(s). 	e order in which they were filed un	less applicant instructs otherwise. If	
a. X Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.			
i. Consider the arguments in the Appeal Brief or Rely Brief previously filed on			
ii. X Other Request for Reconsideration filed June 9, 2003 (copy enclosed)			
b. Enclosed			
i. Amendment/Reply	iii. Information	n Disclosure Statement (IDS)	
ii. Affidavit(s)/ Declaration(s)	. N. Other		
2. Miscellaneous			
Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a a. period of			
b. Other	more grade in the second of th		
3. Fees The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed. The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 033975			
i. X RCE fee required under 37 CFR 1.17(e)	10/10/2003 DTES	SSEM1 00000024 033975 09772938	

		come public. Credit card information should not ard information and authorization on PTO-2038.
	SIGNATURE OF APPLICANT,	ATTORNEY, OR AGENT REQUIRED
Name (Print/Type)	Thomas A. Cawley	Registration No. (Attorney/Agent) 40944
Signature	72-11 Cunt	Date October 8, 2003
	CERTIFICATE OF MA	ILING OR TRANSMISSION
	op RCE, Commissioner for Patents, P.O. Box 1450, Alexa	es Postal Service with sufficient postage as first class mail in an envelope indria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark
Name (Print/Type)		
Signature		Date

Extension of time fee (37 CFR 1.136 and 1.17)

Payment by credit card (Form PTO-2038 enclosed)

Other_ Check in the amount of \$_ 01 FC:1801


enclosed

770.00 DA .

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, cell 1-800-PTO-9199 and select option 2.





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1644

Examiner: Phillip Gambel

In re PATENT APPLICATION OF

Nabil HANNA et al.

Application Serial No. 09/772,938

Filed: January 31, 2001

Title: TREATMENT OF B CELL MALIGNANCIES USING COMBINATION OF B CELL

DEPLETING ANTIBODY AND IMMUNE MODULATING ANTIBODY RELATED

APPLICATIONS

REQUEST FOR RECONSIDERATION

Mail Stop AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This is in response to the official action [final rejection] dated April 8, 2003, wherein the claims were rejected under 35 U.S.C § 103(a) as well as the doctrine of obviousness-type double patenting.